Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
A legfontosabb adatok
- Ki végzi
- Sanofi
- Hol
- Houston (Egyesült Államok)A helyszín megnézéseMég 5 másik országban, 10 helyszínen
- Azonosító
- NCT05013554
- EU 2023-506852-26-00
- EudraCT 2021-000086-32
- U1111-1253-2233
- Állapot
- Leállítva
- Fázis
- 1. fázis
- Résztvevők
- 44 fő vett részt
- Kezdés
- 2021. aug. 16.
- Befejezés
- 2024. jan. 15.
- A vizsgálat típusa
- Beavatkozással járó, 5 csoport
- A vizsgált kezelések
- SAR443216 IV
- SAR443216 SC
- A regiszteradat frissítve
- 2025. szeptember 15.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Participants must be ≥ 18 years of age
- Histologically or cytologically confirmed diagnosis of metastatic solid tumors
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- All participants should have at least 1 measurable disease per RECIST v1.1. An irradiated lesion can be considered measurable only if progression has been demonstrated on the irradiated lesion
- Body weight within [45 - 150 kg] (inclusive)
- All Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- Capable of giving signed informed consent
Ki nem vehet részt
- Prior solid organ or hematologic transplant
- Participation in a concurrent clinical study in the treatment period
- Any clinically significant cardiac disease
- History of or current interstitial lung disease or pneumonitis
- Uncontrolled or unresolved acute renal failure
- Known positivity with human immunodeficiency virus (HIV), known active hepatitis A, B, and C, or uncontrolled chronic or ongoing infectious requiring parenteral treatment
- Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions; The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial
- Receipt of a live-virus vaccination within 28 days of planned treatment start
- Inadequate hematologic, hepatic and renal function
Helyszínek itt: Egyesült Államok
Még 5 másik országban, 10 helyszínen
- ~University of Texas - MD Anderson Cancer Center Site Number : 8400002Houston, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
Primary Objectives:
A teljes eredeti leírásKevesebb
Part 1 (Dose Escalation)
* To determine the MTD/maximum administered dose (MAD) of SAR443216 administered as a single agent in participants with HER2 expressing solid tumors and determine the RD(s) for intravenous (IV) and subcutaneous (SC) administration in the dose escalation part. * To determine the safety of SAR443216 after intravenous (IV) and subcutaneous (SC) administration.
Part 2 (Dose expansion)
• To assess preliminary clinical activity of single agent SAR443216 at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.
Secondary Objectives:
Part 1 • To assess preliminary clinical activity of single agent SAR443216 after IV and SC administration at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.
Part 2
• To determine the safety of SAR443216.
Part 1 and 2
* To characterize the pharmacokinetic (PK) profile of SAR443216 when administered as a single agent after IV and SC (Part 1 only) administration. * To evaluate the immunogenicity of SAR443216 after IV and SC administration. * To assess preliminary clinical activity of single agent SAR443216 at the RD(s) in participants with HER2 expressing solid tumors, with various levels of HER2 expression.
A vizsgálat 5 csoportja
- SAR443216-Dose EscalationA vizsgált kezelés
Participants with metastatic solid tumors that express HER2 in tumor tissue and/or with HER2 aberration will receive SAR443216 as intravenous (IV) infusion or subcutaneous (SC) injection.
Kezelés: SAR443216 IV és SAR443216 SC
- SAR443216-Dose Expansion - metastatic breast cancers with HER2 high expression: Cohort AA vizsgált kezelés
Participants with metastatic breast cancers with HER2 high expression (with amplification) will receive SAR443216 as intravenous (IV) infusion.
Kezelés: SAR443216 IV
- SAR443216-Dose Expansion- metastatic breast cancers with HER2 low expression: Cohort BA vizsgált kezelés
Participants with metastatic breast cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.
Kezelés: SAR443216 IV
- SAR443216-Dose Expansion- metastatic gastric cancers with HER2 low expression: Cohort CA vizsgált kezelés
Participants with metastatic gastric cancers with HER2 low expression or HER2 mutation (without amplification) will receive SAR443216 as intravenous (IV) infusion.
Kezelés: SAR443216 IV
- SAR443216-Dose Expansion - metastatic NSCLC with HER2 low or high expression: Cohort DA vizsgált kezelés
Participants with metastatic NSCLC with HER2 low or high expression and/or HER2 mutation will receive SAR443216 as intravenous (IV) infusion.
Kezelés: SAR443216 IV
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- A Phase 1/1b Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors.
- A regiszteradat frissítve
- 2025. szeptember 15.